Interdisciplinary and translational oncology
As a result of the increasing complexity of oncological therapy concepts as well as the increasing number of long-term survivors following multimodal therapy concepts, prediction and prognosis remain a particular challenge in order to ensure the best possible course of therapy. Our working group aims at mapping the treatment reality to identify and characterize patient and tumour characteristics in order to enable the transition of risk strata and prognostic factors from individual cases to broad application. For that, we work together with our partners from the surgical disciplines, radiotherapy and nuclear medicine, as well as pathology and radiology.
Projects
For:
- localized head and neck tumors
- advanced head and neck tumors (among others)
- HEAT (multicenter registry, in cooperation with AIO)
- soft tissue sarcomas
- renal cell carcinomas (among others):
- PreNikaDika
- Revaluate (multicenter registry)
- Relevance (multicenter registry)
- GUARDIAN (multicenter registry, in cooperation with AIO)
- Urinary bladder tumors
- Enfortumab-Vedotin Registry (multicenter registry; cooperation WTD-Essen)
Targeted cancer therapy is a treatment with drugs that specifically intervene in processes that are important for tumor growth. However, even though drugs are primarily directed against properties of tumor cells, some of the same structures also occur in healthy cells which favors side effects/toxicities.
Precision oncology describes the use of targeted therapeutics and cross-histology therapy strategies based on molecular tumour characterization with the aim of personalized therapy control.
